FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Communicate Considerations to IDE Sponsors: Letters

[ Price : $8.95]

St. Jude Medical and Covidien recommend that FDA communicate future and study design considerations to IDE sponsors outside of the...

Janssen Recalls 1 Risperdal Lot Over Mold Concerns

[ Price : $8.95]

Johnson & Johnson drug unit Janssen Pharmaceuticals recalls one lot of antipsychotic drug Rispedal Consta (risperidone) long-actin...

Gilead Sciences NDA for non-Hodgkins Lymphoma

[ Price : $8.95]

Gilead Sciences files an NDA for idelalisib, an investigational targeted oral inhibitor of PI3K delta for treating indolent non-Ho...

ODAC Recommends Accelerated Perjeta Approval

[ Price : $8.95]

FDAs Oncologic Drugs Advisory Committee recommends accelerated approval for Genentechs Perjeta for an indication for neoadjuvant t...

OvaScience Suspending Augment Enrollment in U.S.

[ Price : $8.95]

OvaScience says it is suspending U.S. enrollment of its Augment in vitro fertilization egg enhancement product while it discusses ...

FDA Extends Comments on Cigarette/Menthol Regulation

[ Price : $8.95]

Federal Register Advance notice of proposed rulemaking: FDA extends the comment period to 11/22 on a 7/24 request for comments on ...

Woodcock Praises GDUFA Staff Work

[ Price : $8.95]

CDER director Janet Woodcock says the GDUFA Human Capital Team has hired and trained 234 new employees for GDUFA implementation.

Temple Says CDER Tougher on Stupid Trial Subpopulation Exclusions

[ Price : $8.95]

CDER deputy director for clinical science Bob Temple says drug reviewers are becoming more aggressive with drug sponsors and their...

CDER is Enthusiastic About Patient-reported Outcomes: Temple

[ Price : $8.95]

Addressing criticism that patients subjective self-assessments have been identified as generally not reliable or informative, CDER...

Inspection Guidance Leaves Questions Unanswered: Lawyers

[ Price : $8.95]

Alston & Bird attorneys say an FDA draft guidance on inspection refusals raises additional questions and potential areas of misund...